BioTheryX Inc, a United States-based clinical-stage company, has named Robert F Williamson, III as its new president and chief executive officer and a member of the company's board of directors, it was reported on Thursday.

Williamson was previously chief executive officer of both PharmAkea and ATXCo. Prior to that he was chief executive officer of Arriva Pharmaceuticals, president and COO of Eos Biotechnology and COO of DoubleTwist Inc. He has also served as a board member for privately held and publicly traded companies including member of the board of directors of Pharmasset Inc and member of the board of directors of Progen Pharmaceuticals. Presently, he holds the position of chairman at HAYA Therapeutics SA and as a member of the board of directors of the Coulter Center in Miami. He was a partner with The Boston Consulting Group and also served a research assistant for the Federal Reserve Board.

Williamson graduated from Pomona College with a BA in Economics and an MBA from Stanford GSB.